

**GOVERNING BOARD OF
THE GLOBAL HEALTH EDCTP3 JOINT UNDERTAKING
DECISION N° GB/20/2026**

**Adopting the second modified version of the
Work Programme for the year 2026**

THE GOVERNING BOARD OF THE GLOBAL HEALTH EDCTP3 JOINT UNDERTAKING (hereafter “Global Health EDCTP3”),

Having regard to Council Regulation (EU) No 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014 (hereafter “the Founding Regulation”), in particular Articles 17(2)(f), (k) and (n), 19(4) (c) and 21(7)(a) thereof,

Having regard to Regulation (EU) 2021/695 of the European Parliament and of the Council of 28 April 2021 establishing Horizon Europe - the Framework Programme for Research and Innovation, laying down its rules for participation and dissemination, and repealing Regulations (EU) No 1290/2013 and (EU) No 1291/2013 (hereinafter “the Horizon Europe Regulation”),

Having regard to the Financial Rules of Global Health EDCTP3¹, and in particular Articles 6 and 33 thereof,

WHEREAS:

- (1) On 15 April 2026, the Governing Board adopted the first modified version of the Work Programme 2026 of Global Health EDCTP3 by decision GB/07/2026.
- (2) EUR 16.7 million was de-committed at the beginning of the year related to unused appropriations from previous years.
- (3) The Coalition for Epidemic Preparedness Innovations (CEPI) has submitted a letter of endorsement to the Governing Board on 16 January 2026;
- (4) On 9 March 2026, the Governing Board has approved the application of CEPI by decision GB/05/2026.
- (5) CEPI plans to provide financial contributions to Global Health EDCTP3, which are to be used under topic “HORIZON-JU-GH-EDCTP3-2026-03-SERP-01: training, and innovation networks for sustained capacity building related to ethics, regulatory, pharmacovigilance, and related digital regulatory platforms”.

¹ Governing Board decision GB/22/2022.

- (6) Subject to the approval by the Governing Board of the letter of endorsement from the Novo Nordisk Foundation (NNF), NNF will become a contributing partner and provide a financial contribution of EUR 8.475 million to the call 'Global Collaboration Action for Prevention and Treatment of Lower Respiratory Tract Infections in sub-Saharan Africa'.
- (7) The Leprosy Research Initiative (LRI) will provide a financial contribution of up to EUR 400 000 to support one or more projects with a leprosy component, if any, as part of the 'Global collaboration action for the development of TB drugs for therapy and chemoprophylaxis in adults and children in sub-Saharan Africa'.

On 30 June 2026, the Global Health EDCTP3 Joint Undertaking opened applications to four grants to identified beneficiaries in the context of Mobilisation of Emergency funding for the Ebola Bundibugyo outbreak research response (HORIZON-JU-GH-EDCTP3-2026-01-EBOLA-IBA, HORIZON-JU-GH-EDCTP3-2026-02-EBOLA-IBA, HORIZON-JU-GH-EDCTP3-2026-03-EBOLA-IBA and HORIZON-JU-GH-EDCTP3-2026-04-EBOLA-IBA), on the basis of "Other actions not subject to call for proposals - Mobilisation of research funds in case of Public Health Emergencies" with an increased budget of EUR 4 million.

HAS ADOPTED THIS DECISION:

Article 1

The annex to decision GB/07/2026 (First modified version of the Work Programme 2026 of the Global Health EDCTP3 Joint Undertaking) is hereby replaced by Annex 2 to this decision (Second modified version of the Work Programme for the year 2026).

All substantial modifications to the Work Programme for the year 2026 are described in Annex 1 to this decision (Explanatory note).

Article 2

This decision shall enter into force on the day of its adoption.

Done at Brussels, 20 August 2026.

For the Global Health EDCTP3 Joint Undertaking Governing Board

Maria Pilar Aguar Fernandez
Chairperson of the Governing Board

Annex:

- 1. Explanatory note.
- 2. Second modified version of the Work Programme for the year 2026.